Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Geneos Therapeutics

HQ: Philadelphia, PA source · geneostx.com ↗ · Mid-Atlantic

Clinical Phase 2

Keywords: oncology HCC INO-9012 GNOS-PV02

Location: Philadelphia, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

2026-09 Trial start Phase 2: Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC source ↗
Mar 1, 2020 Trial start Phase 1/Phase 2: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC source ↗

Upcoming milestones

2029-09 (ESTIMATED) · Phase 2 · Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC · NCT07722741

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04251117	GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC	Phase 1/Phase 2	Active, not recruiting	Mar 1, 2020	Nov 29, 2024 (actual)
NCT07722741	Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC	Phase 2	Recruiting	2026-09	2029-09 (estimated)